Phase 3 N=193 A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Fibromyalgia
Primary: Mean NRS Pain Score at End of Period. — 4.84; 5.45 Units on a scale — p=0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=611 Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Myeloid Leukemia, Chronic, Accelerated Phase · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…
Phase 2 N=167 A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Hepatitis C
Primary: Number of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Planned End of Treatment (EOT) — 19; 14; 26; 13 Participants
Phase 2 N=105 Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Leukemia · Lymphoma
Primary: Complete Response Rate — 83 percentage of participants
N/A N=207 Considering Patient Diet Preferences to Optimize Weight Loss
Obesity
Primary: Percent Change in Body Weight From Baseline to 48 Weeks — -4.2; -5.3 percentage of weight change — p=<0.05
Phase 4 N=98 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Symptomatic Orthostatic Hypotension
Primary: Percent of Subjects Who Failed to Maintain a Response — 30.3; 44.1 percentage of participants — p=0.3145
Phase 1 N=50 A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide — 14700; 14300 nanograms times hours per milliliters
Phase 2 N=21 Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
Marijuana Abuse
Primary: Marijuana Use — 2.5; 3.9 Reported uses per day
Phase 2 N=76 A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With an Infusion Reaction Within 24 Hours After Infusion — 29.7; 17.9 percentage of participants — p=0.238
Phase 3 N=27 Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon
Type 1 Diabetes · Dawn Phenomenon
Primary: Blood Glucose Area Under the Curve (AUC) — 1673.33; 1395 mg*10hr/dL — p=<0.05
Phase 2 N=8 Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
Ovarian Cancer · Primary Peritoneal Cancer
Primary: The Cystostatic, Anti-tumor Activity of the Combination of Gleevec and Gemzar Via Progression-free Survival for at Least Six Months in Patients With Recurrent or…
N/A N=27 Piloting IVR (Interactive Voice Response) for Chronic Pain Treatment
Chronic Pain
Primary: Comprehension — 92.14; 96.42 Percent of questions answered correctly
Phase 4 N=17 Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
Alzheimer's Disease
Primary: N-acetylaspartate — 1.35; 1.86; 1.58; 1.26 NAA/creatine Ratio
Phase 4 N=31 The Role of Montelukast in Rhinitis and Sleep
Perennial Allergic Rhinitis
Primary: Change From Baseline in Fatigue and Daytime Sleepiness at 2 Weeks — -0.64; 0.13; 0.46; -0.25 units on a scale
Phase 2 N=22 This is a Study to Determine the Antidepressant Effects of AZD6765
Treatment Resistant Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. — 26.881; 28.618; 25.381; 29.718 Units on a scale